DEF: Adaptive Biotechnologies 2026 Proxy Statement

Adaptive Biotechnologies Corporation announces its 2026 Annual Meeting of Shareholders to be held virtually on June 5, 2026.

Summary

• The 2026 Annual Meeting of Shareholders will be held virtually on June 5, 2026, at 9:00 a.m. Pacific Time.
• Shareholders will vote on the election of two Class I directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for 2026.
• 2025 revenue reached $277.0 million, up from $179.0 million in 2024, driven by a $66.8 million increase in the MRD business.
• Net cash used in operations decreased by 52% to $46.0 million in 2025 compared to $95.2 million in 2024.
• As of December 31, 2025, the company held $227.2 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive indicator of operational maturity, as the company has successfully reduced cash burn and achieved profitability in its primary business segment while maintaining strong shareholder support.

Positives

• Significant revenue growth of 54.7% year-over-year ($277.0 million in 2025 vs $179.0 million in 2024).
• Substantial improvement in operational cash flow, with net cash used in operations reduced by 52%.
• MRD business achieved quarterly adjusted EBITDA profitability beginning in Q2 2025.
• Strong shareholder support for executive compensation, with 98.8% approval in the most recent Say-on-Pay vote.
• Expansion of clonoSEQ test volume by 39% year-over-year to 105,587 tests.

Negatives

• The company missed its internal cash burn target for the Immune Medicine business in 2025.
• The special PSU award granted to the Chief Commercial Officer, MRD, was forfeited due to performance metrics not being met.
• Continued reliance on equity-based compensation, which contributes to shareholder dilution.

Risks

• Stock price volatility impacting equity compensation and dilution management.
• Potential for future shareholder efforts to effect changes in management or control due to the staggered board structure.
• Dependence on the success of the MRD business and the ability to maintain profitability.
• Regulatory and compliance risks associated with clinical laboratory testing and medical device manufacturing.

Future Outlook

The company aims to continue its growth trajectory in the MRD business, focusing on expanding payor coverage and clinical adoption, while prioritizing investments in data development and diagnostics within the Immune Medicine segment.

Management Comments

• The board believes the combined role of chairperson and chief executive officer promotes united leadership and direction.
• The company is committed to operating in an environmentally responsible and efficient manner to support long-term value creation.

Industry Context

StockSavvy.ai notes that Adaptive Biotechnologies is successfully transitioning from a high-growth, cash-burning biotech phase toward operational efficiency and profitability in its core MRD business, a trend increasingly demanded by investors in the current macroeconomic environment.

Comparison to Industry Standards

• The company's 46% growth in MRD revenue and 39% increase in test volume demonstrate strong competitive positioning against other diagnostic providers.
• The shift toward performance-based stock units (PSUs) for executive compensation aligns with broader industry trends to tie pay more closely to total shareholder return (TSR).
• The company's commitment to environmental, social, and governance (ESG) reporting, including CDP and Ecovadis ratings, aligns with standard practices for mid-cap biotechnology firms.

Corporate Governance

Related Party Transactions

• Chad Robins (CEO) and Harlan Robins (CSO) are brothers.
• Digital Biotechnologies, Inc. (DigitalBio) is a subsidiary in which certain executive officers and their affiliates hold minority interests.
• The company provides shared services to DigitalBio, with a value of $8.3 million as of December 31, 2025.

Stakeholder Impact

• Shareholders are asked to vote on key governance and compensation matters.
• Employees benefit from a total rewards package and equity grants designed to foster a sense of shared ownership.
• Suppliers are expected to adhere to a Supplier Code of Conduct regarding environmental and safety standards.

Next Steps

• Hold the 2026 Annual Meeting of Shareholders on June 5, 2026.
• Elect two Class I directors.
• Conduct advisory vote on executive compensation.
• Ratify the appointment of Ernst & Young LLP as independent auditor.

Key Dates

Recommendation

The company is showing solid operational progress and improved financial discipline, but the stock remains subject to the inherent risks of the biotechnology sector and the ongoing transition to profitability.

Keywords

Adaptive Biotechnologies, ADPT, Proxy Statement, MRD, clonoSEQ, Immune Medicine, Annual Meeting, Biotechnology